ROCKVILLE, Md.--(BUSINESS WIRE)--Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that members of the Company’s management team will present a corporate overview at two upcoming investor conferences:
